

Inflammatory stress on induced neurons carrying Parkinson's disease-associated LRRK2 Mutations

Jose Torrellas¹, Aravindraja Chairmandurai^{1,2}, Adamantios Mamais^{1,2}, Matthew LaVoie^{1,2}, Paramita Chakrabarty¹

¹ Department of Neuroscience, University of Florida College of Medicine, Gainesville, Florida, USA

² Department of Neurology, University of Florida College of Medicine, Gainesville, Florida, USA

Mutations in the leucine-rich repeat kinase 2 (*LRRK2*) gene, particularly the *G2019S* and *R1441C* variants, are the most prevalent genetic determinants of Parkinson's disease (PD). *LRRK2* is increasingly recognized for its roles in immune signaling, with studies suggesting that interferon-gamma (IFN γ), a master immune regulator, may modulate its activity. Based on these findings, we hypothesize a synergistic interaction between *LRRK2* mutations and IFN γ . To explore this hypothesis, we utilized neurons derived from human induced pluripotent stem cells (iPSCs) harboring homozygous *G2019S* or *R1441C* *LRRK2* mutations, with isogenic wildtype (WT) controls. After differentiation into neurons, cells were treated with recombinant human IFN γ or control media on DIV-17 and harvested after 6 hours of treatment. Six experimental conditions were analyzed: (WT + IFN γ , WT + Control, *G2019S* + IFN γ , *G2019S* + Control, *R1441C* + IFN γ , *R1441C* + Control). We analyzed these experiments using immunoblotting and immunofluorescence methods to assess interferon-pathways, tau phosphorylation, and *LRRK2* substrate engagement. Using a dose-dependent paradigm, we optimized the minimum IFN γ dose to achieve maximal target engagement (STAT1 and phosphorylated-STAT1, pSTAT1). We found that levels of pSer202 tau (CP13) levels were moderately increased in *G2019S* and *R1441C* neurons following IFN γ treatment, but not in wildtype neurons. IFN γ treatment phosphorylated Threonine73 on Rab10 (a *LRRK2* substrate) more efficiently in *G2019S*-*LRRK2* neurons compared to *R1441C*-*LRRK2*. This data lays the groundwork for future studies to dissect mechanisms of neuronal vulnerability in PD and the interplay between *LRRK2* mutations and disease pathways.

Sponsored By: NIH/NIA T32 AG061892

Presenter Name and contact information:

Jose Torrellas, B.S, Graduate Student
Department of Neuroscience
University of Florida, College of Medicine
Gainesville, Florida, USA
Email: jtorrellas@ufl.edu